Physician profile
Mark R Fleckner
NPI 1225063274
$1,205.15
in general payments reported to CMS, 2019-2025
15 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.29 · 2022: $56.19 · 2023: $256 · 2024: $475 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $238.38 | 2022-2025 | |
| Alcon Vision LLC | $210.85 | 2023-2025 | Simbrinza |
| Genentech USA, INC. | $205.33 | 2023-2025 | Vabysmo |
| Astellas Pharma US INC | $131.60 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $131.60 | 2023-2025 | Doctors Allergy Formula |
| Mallinckrodt Hospital Products INC. | $51.04 | 2023 | Acthar |
| Sun Pharmaceutical Industries INC. | $48.60 | 2022-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $36.68 | 2019 | |
| Biogen, INC. | $24.39 | 2023 | |
| Inspire Medical Systems, INC. | $24.35 | 2025 | Inspire |
| Tarsus Pharmaceuticals, INC. | $24.20 | 2025 | Xdemvy |
| Mallinckrodt Enterprises LLC | $22.61 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.06 | 2024 | Syfovre |
| Oyster Point Pharma, INC. | $17.47 | 2024 | Tyrvaya |
| Horizon Therapeutics Plc | $16.99 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fleckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.